A detailed history of Goldman Sachs Group Inc transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 308,678 shares of LUCD stock, worth $308,678. This represents 0.0% of its overall portfolio holdings.

Number of Shares
308,678
Previous 86,302 257.67%
Holding current value
$308,678
Previous $128,000 176.56%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

BUY
$1.09 - $1.65 $242,389 - $366,920
222,376 Added 257.67%
308,678 $354,000
Q1 2025

May 09, 2025

BUY
$0.79 - $1.59 $17,954 - $36,135
22,727 Added 35.75%
86,302 $128,000
Q4 2024

Feb 11, 2025

BUY
$0.76 - $1.08 $48,317 - $68,661
63,575 New
63,575 $50,000
Q1 2022

May 16, 2022

SELL
$2.85 - $5.24 $69,939 - $128,589
-24,540 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$4.87 - $11.76 $119,509 - $288,590
24,540 New
24,540 $132,000

Others Institutions Holding LUCD

About Lucid Diagnostics Inc.


  • Ticker LUCD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 38,568,500
  • Market Cap $38.6M
  • Description
  • Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...
More about LUCD
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.